LTR Pharma (ASX: LTP) has confirmed the first patient-specific ROXUS® prescriptions received through Mavrox, Shed’s men’s health telehealth platform, have now been fulfilled in the United States. 

ROXUS is LTR Pharma’s intranasal medication for erectile dysfunction support. 

The milestone marks the start of prescription activity under LTR Pharma’s agreements with U.S. partners Shed and Strive Pharmacy. LTR Pharma will continue working with Shed and Strive Pharmacy to support ROXUS prescription fulfilment through Mavrox, and will provide further updates on U.S. prescription activity as meaningful information becomes available. 

LTR Pharma Executive Chairman, Lee Rodne, said: 

“Fulfilment of the first ROXUS prescriptions in the United States is an important milestone for LTR Pharma and our US partners. With our first prescriptions now received through Mavrox, we have moved from implementation to serving patients under these arrangements. Our focus is now on supporting our partners as prescribing and prescription activity builds. This milestone comes less than three months after we announced our agreement with Shed to establish a U.S. telehealth route to patients.” 

Read the full ASX announcement 

ROXUS is a compounded medication prepared for identified individual patient needs based on a valid prescription from a prescribing healthcare practitioner and, as such, is not reviewed or approved by the U.S. Food and Drug Administration (FDA) for safety or efficacy. Compounded drugs are intended for patients whose prescriber has determined their medical needs are not met by an available FDA-approved drug. These statements have not been evaluated by the FDA. Prescribers should use their independent clinical judgement when determining appropriateness for individual patients.